机构：[1]Department of Gynaecologic Oncology, Sichuan Cancer Hospital & Institute, Cancer Hospital Affiliated to School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China四川省人民医院四川省肿瘤医院[2]Department of Ultrasound, Sichuan Cancer Hospital & Institute, Cancer Hospital Affiliated to School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China四川省人民医院四川省肿瘤医院[3]Department of Obstetrics and Gynecology, Sichuan Jinxin Women and Children’s Hospital, Chengdu 610000, China[4]Department of Biochemistry & Molecular Biology, Sichuan Cancer Hospital & Institute, Cancer Hospital Affiliated to School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China四川省人民医院四川省肿瘤医院
Background: Cluster of differentiation 44 (CD44)/myeloid differentiation factor 88 (MyD88) is the molecular characterization of EOC stem cells. An important characteristic of CD44+/MyD88+ epithelial ovarian cancer (EOC) cells, which differentiate them from the CD44-/MyD88- EOC cells, is the presence of a functional TLR4-MyD88-NFkB pathway. The aim of our study is to investigate the clinical significance of CD44/MyD88 co-expression in EOC. Methods: A total of 138 specimens of ovarian tissues was detected CD44 and MyD88 expression by immunocytochemistry, including EOC (N=108), borderline tumors (N=10), benign cysts (N=10) and normal ovarian tissue (N=10). The association of CD44/MyD88 co-expression with clinicopathological factors and outcomes was analyzed. Results: The expression of CD44 was showed distinct difference in EOC (53 of 108, 49.1%), in borderline tumors (3 of 10, 30.0%), in benign cysts (2 of 10, 20.0%) and normal ovarian (2 of 10, 20.0%). A total of 41 (38.0%) cancers showed a combined expression of CD44/MyD88. The expression of CD44 and MyD88 had definitely correlativity (r=0.21, P=0.026). CD44/MyD88 co-expression was associated with tumor progression, metastasis, and recurrence in advanced EOC, and an independent prognostic factor for disease-free survival and overall survival. Conclusions: CD44/MyD88 co-expression has been shown to contribute to EOC progression and outcome directly and has a promising as a therapeutic target in EOC.
基金：
Sichuan Key Research and Development Project from Sichuan Provincial Science and Technology Department [19ZDYF0716]
第一作者机构：[1]Department of Gynaecologic Oncology, Sichuan Cancer Hospital & Institute, Cancer Hospital Affiliated to School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China[2]Department of Ultrasound, Sichuan Cancer Hospital & Institute, Cancer Hospital Affiliated to School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Gynaecologic Oncology, Sichuan Cancer Hospital & Institute, Cancer Hospital Affiliated to School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China[4]Department of Biochemistry & Molecular Biology, Sichuan Cancer Hospital & Institute, Cancer Hospital Affiliated to School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China[*1]Department of Gynaecologic Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, No. 55, Section 4, South People’s Road, Chengdu 610041, China.
推荐引用方式(GB/T 7714)：
Zhu Yi,Zhang Hongtao,Zhang Guonan,et al.Co-expression of CD44/MyD88 is a poor prognostic factor in advanced epithelial ovarian cancer[J].ANNALS OF TRANSLATIONAL MEDICINE.2019,7(5):doi:10.21037/atm.2019.01.28.
APA：
Zhu, Yi,Zhang, Hongtao,Zhang, Guonan,Shi, Yu&Huang, Jianming.(2019).Co-expression of CD44/MyD88 is a poor prognostic factor in advanced epithelial ovarian cancer.ANNALS OF TRANSLATIONAL MEDICINE,7,(5)
MLA：
Zhu, Yi,et al."Co-expression of CD44/MyD88 is a poor prognostic factor in advanced epithelial ovarian cancer".ANNALS OF TRANSLATIONAL MEDICINE 7..5(2019)
